NovoCure Ltd. (NVCR)

NovoCure's stock price has declined significantly in the past six months. In January 2026, the share price was $13.77, a 53.57% decrease from $29.66 in January 2025. NovoCure reported preliminary net revenues of $655.4 million for fiscal year 2025 and Q4 revenue of $174.4 million, exceeding expectations, but shares traded down due to investor concerns about profitability and cash burn. Evercore ISI lowered its price target for NovoCure to $20 from $22, and Frank Leonard was named CEO. In October 2025, NovoCure reported revenues of US$167.2 million, an 8% increase year-over-year, but a higher net loss of US$37.27 million. The company announced progress in expanding European and Asian market access, including a positive national coverage decision in Spain for TTFields therapy. Voya Investment Management LLC sold a significant portion of its NovoCure shares in Q3 2025.

Information regarding demand seasonality for NovoCure Ltd.'s products and services is available, with data displaying mean and median monthly returns for NVCR to identify seasonal patterns. However, the specific seasonal patterns or their impact on demand are not detailed.

NovoCure Ltd. is an oncology company focused on developing and commercializing therapies for solid tumor cancers, operating in the Healthcare sector, specifically in the Medical Equipment and Instruments & Supplies industry. Their core technology, Tumor Treating Fields (TTFields), uses electric fields to disrupt cancer cell division. Major commercialized products include Optune Gio for glioblastoma and Optune Lua for malignant pleural mesothelioma. The company has a pipeline with clinical trials investigating TTFields for various cancers, including brain metastases, gastric cancer, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer, with products like Trident, Lunar-2, Panova-3, and Metis.

NovoCure Ltd. has a global presence with headquarters in Baar, Switzerland, and operational locations in the USA, Germany, France, Israel, Japan, and Canada. They have a strategic partnership with Zai Lab for market access in Greater China. The majority of its revenue comes from the United States, with additional contributions from Germany, Japan, and other international markets.

NovoCure's brand reputation has been influenced by regulatory approvals and clinical milestones, such as approval from Japan for Optune Lua for non-small cell lung cancer and FDA approval for Optune Lua for metastatic NSCLC. Expanding international coverage, including a national coverage decision in Spain, reflects increased recognition and adoption potential. However, the company faces challenges in expanding the utility of its TTFields technology beyond glioblastoma, with new indications contributing minimally to revenue and facing adoption challenges. Analysts have expressed concerns, citing limited expansion potential and declining gross margins, impacting its reputation regarding future growth and financial health.

NovoCure Limited's ownership is a mix of institutional, retail, and individual investors. Institutional investors hold approximately 84.61% of the company's stock. Major institutional owners include Fmr Llc, BlackRock, Inc., Vanguard Group Inc, Soleus Capital Management, L.P., State Street Corp, Fidelity Growth Company Fund (FDGRX), SMALLCAP WORLD FUND INC Class A (SMCWX), Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), GROWTH FUND OF AMERICA Class A (AGTHX), and Vanguard Small-Cap Index Fund Investor Shares (NAESX). Insiders own approximately 2.19% of the company's stock.